ArticleEuropean journal of pediatrics2025
Clinical characteristics of children with anti-N-methyl-D-aspartate receptor encephalitis with and without anti-myelin oligodendrocyte glycoprotein antibody.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Case Report: Overlap syndrome of anti-NMDA receptor encephalitis and MOG-associated disease in a pediatric patient-literature insights.Frontiers in immunology · 2026Review
- Altered tyrosine metabolism and B lymphocyte profiles are associated with disease severity in pediatric anti-NMDAR encephalitis: a cross-sectional study.European journal of pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
To analyze the clinical characteristics of an overlapping syndrome, MNOS, of anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab) coexisting with anti-N-methyl-D-aspartate receptor encephalitis (NMDARE) in children. We included patients with NMDARE at Children's Hospital of Chongqing Medical University between 2018 and 2022 and conducted a comparison between NMDARE with and without MOG-Ab. Among 163 patients with NMDARE, 15 individuals tested positive for MOG-Ab. The median age of MNOS was 11 years (IQR 8-13). Furthermore, 10 out of 15 were female. More than half of MNOS experienced a prior history of encephalitis or demyelinating disorders. Among ten patients with low MOG-Ab titers, two met the diagnostic criteria for MOGAD. All five patients with high MOG-Ab titers satisfied the criteria for MOGAD. A total of seven patients diagnosed with MOGAD presented with acute disseminated encephalomyelitis. The proportion of prodromal symptoms and brain lesions, the neutrophil counts, and the frequency of mycophenolate mofetil administration were significantly higher in MNOS compared to NMDARE patients without MOG-Ab (p < 0.05). The outcomes of MNOS were favorable and comparable to those observed in NMDARE. Nevertheless, MNOS demonstrated a higher tendency to relapse, with rates of 60.0% compared to 3.1% (p < 0.001).
conclusionPediatric MNOS exhibited a high prevalence among females, particularly those with a prior history of MOGAD or encephalitis. MNOS had a favorable prognosis but with a high relapse rate. Coexisting MOG-Ab in pediatric MNOS may be pathogenic or a bystander, potentially correlating with antibody titers. WHAT IS KNOWN: • Pediatric anti-N-methyl-D-aspartate receptor encephalitis (NMDARE) coexisting with anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab) generally has a favorable prognosis, albeit with a tendency to relapse. • Pediatric NMDARE coexisting with MOG-Ab may exhibit imaging features indicative of demyelination. WHAT IS NEW: • Pediatric patients of MOG-Ab coexisting with NMDARE overlapping syndrome (MNOS) were predominantly observed in females, particularly those with a history of MOG-Ab-associated disorder (MOGAD) or encephalitis. • Compared with NMDARE patients, pediatric MNOS patients had higher neutrophil counts and more frequently exhibited abnormal MRI findings in the basal ganglia, insular lobe, temporal lobe, thalamus, and cerebellum.
Indexed as
Identifiers
40082268What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.